ZUSDURI Drug Patent Profile
Which patents cover Zusduri, and what generic alternatives are available?
Zusduri is a drug marketed by Urogen Pharma and is included in one NDA. There are five patents protecting this drug.
The generic ingredient in ZUSDURI is mitomycin. There is one drug master file entry for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the mitomycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zusduri
A generic version of ZUSDURI was approved as mitomycin by HIKMA on April 19th, 1995.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ZUSDURI?
- What are the global sales for ZUSDURI?
- What is Average Wholesale Price for ZUSDURI?
Summary for ZUSDURI
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 4,762 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ZUSDURI |
| What excipients (inactive ingredients) are in ZUSDURI? | ZUSDURI excipients list |
| DailyMed Link: | ZUSDURI at DailyMed |
US Patents and Regulatory Information for ZUSDURI
ZUSDURI is protected by five US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urogen Pharma | ZUSDURI | mitomycin | POWDER;INTRAVESICAL | 215793-001 | Jun 12, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Urogen Pharma | ZUSDURI | mitomycin | POWDER;INTRAVESICAL | 215793-001 | Jun 12, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Urogen Pharma | ZUSDURI | mitomycin | POWDER;INTRAVESICAL | 215793-001 | Jun 12, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Urogen Pharma | ZUSDURI | mitomycin | POWDER;INTRAVESICAL | 215793-001 | Jun 12, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Urogen Pharma | ZUSDURI | mitomycin | POWDER;INTRAVESICAL | 215793-001 | Jun 12, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Urogen Pharma | ZUSDURI | mitomycin | POWDER;INTRAVESICAL | 215793-001 | Jun 12, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZUSDURI
See the table below for patents covering ZUSDURI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 212011100034 | ⤷ Start Trial | |
| Denmark | 2525777 | ⤷ Start Trial | |
| European Patent Office | 2525777 | MATÉRIEL ET PROCÉDÉ DE TRAITEMENT DE CAVITÉS INTERNES (MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES) | ⤷ Start Trial |
| European Patent Office | 2734187 | MATÉRIAUX ET MÉTHODE DE TRAITEMENT DE CAVITÉS CORPORELLES INTERNES (MATERIALS AND METHOD FOR TREATING INTERNAL BODY CAVITIES) | ⤷ Start Trial |
| Spain | 2732150 | ⤷ Start Trial | |
| Israel | 221040 | חומר ושיטה לטיפול בחללי גוף פנימיים (Material and method for treating internal cavities) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch